The combo, decitabine and cedazuridine tablets plus venetoclax, was approved for adults aged 75 and older and adults with comorbidities that preclude intensive induction chemotherapy.

The study adds evidence that obesity treatment benefits depend on continued therapy, even when the delivery method changes.

In addition to reducing OR burden and its accompanying costs, offering nitrous oxide for in-office procedures can be easier ...

The TECNO trial finds no clear reperfusion benefit from intra-arterial thrombolysis after thrombectomy in acute ischemic ...

The rise of new weight-loss drugs could help reframe obesity as a societal failure driven by the food industry, rather than ...

Fecal metabolomic profiling in Crohn’s disease reveals distinct metabolite patterns linked to disease activity, location, and ...

Virtual neurology care for new patients is comparable to in-person care, with similar 90-day follow-up rates, ED visits, and ...

ERS urges uniform training, equitable therapy access and harmonized data systems to cut respiratory health disparities amid aging populations and environmental threats.

The drug, widely used for chemotherapy-related nausea, may also be highly effective for symptoms caused by abdominal-pelvic ...

Empagliflozin and dapagliflozin show similar effectiveness in preventing cardiorenal outcomes among patients with type 2 ...

Feeling more stressed is linked to irregular sleep patterns and problems in teens, whereas living in a supportive ...

Adults with T1D who receive GLP-1-based therapy may have a lower risk for adverse cardiovascular outcomes and no significant ...